ScottJayJacoberDO

PubMed

• 2 citations
  Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins.
  Arun J. Sanyal, Kenneth Cusi, Mark L. Hartman, Shuyu Zhang, Edward J. Bastyr, Juliana M. Bue-Valleskey, Annette M. Chang, Axel Haupt, Scott J. Jacober, Robert J. Konra...> ;Journal of Investigative Medicine. 2018 Mar 1
• 5 citations
  Relationship of Glucose Variability With Glycated Hemoglobin and Daily Mean Glucose: A Post Hoc Analysis of Data From 5 Phase 3 Studies:
  Junxiang Luo, Yongming Qu, Qianyi Zhang, Annette M. Chang, Scott J. Jacober> ;Journal of Diabetes Science and Technology. 2018 Mar 1
• 8 citations
  Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glar...
  Rakel Fuglsang Johansen, Esben Søndergaard, Helle Linnebjerg, Parag Garhyan, Eric Chen Quin Lam, Niels Porksen, Scott J. Jacober, Søren Nielsen> ;Diabetes, Obesity & Metabolism. 2018 Feb 1
• 4 citations
  Dose Unit Establishment for a New Basal Insulin Using Joint Modeling of Insulin Dose and Glycemic Response.
  Yongming Qu, Junxiang Luo, Parag Garhyan, Caryl J. Antalis, Annette M. Chang, Scott J. Jacober> ;Journal of Diabetes Science and Technology. 2018 Jan 1
• Novel hepato‐preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and t...
  Niels Porksen, Helle Linnebjerg, Parag Garhyan, Eric Chen Quin Lam, Mary Pat Knadler, Scott J. Jacober, Ulrike Hoevelmann, Leona Plum‐Moerschel, Elaine Watkins, Amalia...> ;Diabetes, Obesity & Metabolism. 2017 Apr 1
• 16 citations
  Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials
  Henry N. Ginsberg, Bertrand Cariou, Trevor J. Orchard, Lei Chen, Junxiang Luo, Edward J. Bastyr, Juliana M. Bue-Valleskey, Annette M. Chang, Tibor Ivanyi, Scott J. Jac...> ;Diabetes, Obesity & Metabolism. 2016 Nov 1
• Randomized, Double-Blind Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination with Prandial Insulin Lispro, in Patients with Type 1 Di...
  S J Jacober, R M Bergenstal> ;Diabetes, Obesity and Metabolism. 2016-11-01
• 39 citations
  Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial
  Melanie J. Davies, David Russell-Jones, J.‐L. Selam, T. S. Bailey, Z. Kerényi, Junxiang Luo, Juliana M. Bue-Valleskey, Tibor Ivanyi, Mark L. Hartman, Jennie G. Jacobso...> ;Diabetes, Obesity & Metabolism. 2016 Aug 12
• 7 citations
  Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossove...
  Linda Morrow, Marcus Hompesch, Scott J. Jacober, S. Leng Choi, Yongming Qu, Vikram Sinha> ;Diabetes, Obesity & Metabolism. 2016 Nov 1
• 25 citations
  Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action.
  Scott J. Jacober, Melvin J. Prince, John Michael Beals, Mark L. Hartman, Yongming Qu, Helle Linnebjerg, Parag Garhyan, Axel Haupt> ;Diabetes, Obesity & Metabolism. 2016 Oct 10
• 28 citations
  Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.
  Kenneth Cusi, Arun J. Sanyal, Shuyu Zhang, Byron J. Hoogwerf, Annette M. Chang, Scott J. Jacober, Juliana M. Bue-Valleskey, A. N. Higdon, Edward J. Bastyr, Axel Haupt,...> ;Diabetes, Obesity & Metabolism. 2016 Oct 10
• 14 citations
  Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.
  Sunder Mudaliar, Robert R. Henry, Theodore P. Ciaraldi, Debra Armstrong, Paivi Burke, Jeremy Pettus, Parag Garhyan, S. L. Choi, Mary Pat Knadler, Eric Chen Quin Lam, M...> ;Diabetes, Obesity & Metabolism. 2016 Oct 10
• 12 citations
  A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial†
  G. Grunberger, Lei Chen, A. Rodriguez, F. J. Tinahones, Scott J. Jacober, Juliana M. Bue-Valleskey> ;Diabetes, Obesity & Metabolism. 2016 Oct 10
• A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAG...
  Garg S, Dreyer M, Jinnouchi H, Mou J, Qu Y, Hartman ML, Rosilio M, Jacober SJ, Bastyr EJ> ;Diabetes Obes Metab. 2016-10-01
• 12 citations
  Factors Associated With Cardiovascular Events in Patients With Type 2 Diabetes and Acute Myocardial Infarction.
  Krzysztof Strojek, Itamar Raz, György Jermendy, Anselm K. Gitt, Rong Liu, Qianyi Zhang, Scott J. Jacober, Zvonko Milicevic> ;The Journal of Clinical Endocrinology and Metabolism. 2016 Jan 1
• 1 citations
  Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1...
  Julio Rosenstock, Thomas Blevins, Richard M. Bergenstal, Linda Morrow, Yongming Qu, Scott J. Jacober> ;Journal of Diabetes. 2016 Jan 1
• 6 citations
  Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin ...
  William V. Tamborlane, Eric Renard, R. Paul Wadwa, Thomas Blevins, Scott J. Jacober, Rong Liu, Deborah N. D'Souza, Tina M. Rees> ;Journal of Diabetes. 2015 Mar 1
• 48 citations
  Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects
  Robert R. Henry, Sunder Mudaliar, Theodore P. Ciaraldi, Debra Armstrong, Paivi Burke, Jeremy Pettus, Parag Garhyan, S. L. Choi, Scott J. Jacober, Mary Pat Knadler, Eri...> ;Diabetes Care. 2014 Sep 1
• 1 citations
  A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulin.
  David H. Manner, Junxiang Luo, Yongming Qu, Scott M. Berry, Brenda Gaydos, Scott J. Jacober> ;Diabetes Technology & Therapeutics. 2014 Jul 29
• 18 citations
  Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM.
  Scott J. Jacober, Julio Rosenstock, Richard M. Bergenstal, Melvin J. Prince, Yongming Qu, John Michael Beals> ;Diabetes, Obesity & Metabolism. 2014 Apr 1
• 25 citations
  Lower Glucose Variability and Hypoglycemia Measured by Continuous Glucose Monitoring With Novel Long-Acting Insulin LY2605541 Versus Insulin Glargine
  Richard M. Bergenstal, Julio Rosenstock, Edward J. Bastyr, Melvin J. Prince, Yongming Qu, Scott J. Jacober> ;Diabetes Care. 2014 Mar 1
• 75 citations
  Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism
  Mary Courtney Moore, Marta S. Smith, Vikram Sinha, John Michael Beals, M. Dodson Michael, Scott J. Jacober, Alan D. Cherrington> ;Diabetes. 2014 Feb 1
• 5 citations
  The effect of adjusting for baseline hypoglycemia when analyzing hypoglycemia data: a systematic analysis of 15 diabetes clinical trials.
  Junxiang Luo, Scott J. Jacober, Melvin J. Prince, Michelle A. Carey, Yongming Qu> ;Diabetes Technology & Therapeutics. 2013 Aug 12
• 1 citations
  Response to Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal I...
  Richard M. Bergenstal, Julio Rosenstock, Richard Arakaki, Melvin J. Prince, Yongming Qu, Vikram Sinha, Daniel C. Howey, Scott J. Jacober> ;Diabetes Care. 2013 Jul 1
• 102 citations
  A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.
  Richard M. Bergenstal, Julio Rosenstock, Richard Arakaki, Melvin J. Prince, Yongming Qu, Vikram Sinha, Daniel C. Howey, Scott J. Jacober> ;Diabetes Care. 2012 Nov 1
• Join now to see all